DK2702172T3 - Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer - Google Patents

Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer Download PDF

Info

Publication number
DK2702172T3
DK2702172T3 DK12724283.2T DK12724283T DK2702172T3 DK 2702172 T3 DK2702172 T3 DK 2702172T3 DK 12724283 T DK12724283 T DK 12724283T DK 2702172 T3 DK2702172 T3 DK 2702172T3
Authority
DK
Denmark
Prior art keywords
cancer
clinically relevant
determining clinically
hypoxia
relevant hypoxia
Prior art date
Application number
DK12724283.2T
Other languages
English (en)
Inventor
Marianne Nordsmark
Jan Alsner
Carsten Wiuf
Jens Overgaard
Brita Singers Sørensen
Kasper Toustrup
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Application granted granted Critical
Publication of DK2702172T3 publication Critical patent/DK2702172T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/4925Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK12724283.2T 2011-04-29 2012-04-30 Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer DK2702172T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201170212 2011-04-29
PCT/DK2012/050144 WO2012146259A1 (en) 2011-04-29 2012-04-30 Method for determining clinically relevant hypoxia in cancer

Publications (1)

Publication Number Publication Date
DK2702172T3 true DK2702172T3 (da) 2020-04-06

Family

ID=46178373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12724283.2T DK2702172T3 (da) 2011-04-29 2012-04-30 Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer

Country Status (10)

Country Link
US (1) US10385399B2 (da)
EP (1) EP2702172B1 (da)
JP (2) JP6081447B2 (da)
AU (2) AU2012247868B2 (da)
CA (1) CA2834588A1 (da)
DK (1) DK2702172T3 (da)
MX (1) MX2013012648A (da)
RU (1) RU2013153096A (da)
WO (1) WO2012146259A1 (da)
ZA (1) ZA201308119B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703188B1 (en) 2012-11-19 2014-04-22 Azanta A/S Dispersible tablet
WO2019075320A1 (en) * 2017-10-12 2019-04-18 The Trustees Of Columbia University In The City Of New York INCARN OF SLC2A1 AS BIOLOGICAL SUBSTANCE, TREATMENTS AND ASSOCIATED METHODS
CN115252603A (zh) * 2022-07-08 2022-11-01 深圳市第二人民医院(深圳市转化医学研究院) indisulam在制备治疗膀胱癌的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007314366A1 (en) 2006-10-30 2008-05-08 Southern Research Institute Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
JP2009011167A (ja) 2007-06-29 2009-01-22 Hiroshima Univ 低酸素応答を制御する物質のスクリーニング方法及び低酸素応答を制御する医薬組成物
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
ES2325724B1 (es) 2008-03-11 2010-05-31 FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" Composicion farmaceutica para inhibir el factor de transcripcion inducible por hipoxia. moduladores de procesos patologicos de angiogenesis, oncogenesis, inflamacion, apoptosis y terapia celular.
GB0922437D0 (en) * 2009-12-22 2010-02-03 Cancer Rec Tech Ltd Hypoxia tumour markers
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles

Also Published As

Publication number Publication date
EP2702172A1 (en) 2014-03-05
AU2016238842B2 (en) 2018-12-13
AU2016238842A1 (en) 2016-10-27
JP6081447B2 (ja) 2017-02-15
MX2013012648A (es) 2014-05-27
US20150159218A1 (en) 2015-06-11
AU2012247868A1 (en) 2013-11-14
US10385399B2 (en) 2019-08-20
ZA201308119B (en) 2020-01-29
JP2014518616A (ja) 2014-08-07
WO2012146259A1 (en) 2012-11-01
JP2017079750A (ja) 2017-05-18
RU2013153096A (ru) 2015-06-10
EP2702172B1 (en) 2020-01-01
AU2012247868B2 (en) 2016-07-07
CA2834588A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK2761553T3 (da) Betalingssystem
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO7020871A2 (es) Anticuerpos anti-il-36r
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
BR112014022692A2 (pt) Molécula de ligação de antígeno multiespecífica
DK2751387T3 (da) Selvsuspenderende proppanter til hydraulisk frakturering
BR112014007958A2 (pt) método
CR20140127A (es) Anticuerpo anti-abtcr
BR112014001237A2 (pt) método
DK2732131T3 (da) Positioneringsfremgangsmåde
BR112014001765A2 (pt) método
DK2732260T3 (da) Prøveopsamlingskit
DK2531526T3 (da) Fremgangsmåde til opnåelse af antistoffer
BR112014009795A2 (pt) método
EP2700030A4 (en) DETERMINATION OF BORE INTEGRITY
DK2876447T3 (da) Fremgangsmåde til detektering af cancer
FI20115703A0 (fi) Näytteenotin
DK2726702T3 (da) Brøndværktøj til bestemmelse af sideboringer
EP2758079A4 (en) PROCESS WITH BIOMARKERS FOR LIVER DISEASE
BRDI7103909S (pt) Perfil de bordeamento
EP2725342A4 (en) CELL FOR OPTICAL ANALYSIS
DK2683371T3 (da) Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere
DK2474236T3 (da) Fremgangsmåde til fremstilling af søde sager
FR2971421B1 (fr) Composition biphase